Phathom Pharmaceuticals (PHAT) Non-Current Assets (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Non-Current Assets data on file, last reported at $28.5 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 2.59% year-over-year to $28.5 million in Q1 2026; TTM through Mar 2026 was $122.6 million, a 62.78% increase from a year earlier, with the FY2025 full-year figure at $30.2 million, up 65.95% from the prior year.
• Non-Current Assets for Q1 2026 stood at $28.5 million, down from $30.2 million in the prior quarter.
• Over the last five years, Non-Current Assets for PHAT reached as high as $32.5 million in Q3 2025 and fell as low as $3.3 million in Q1 2022.
• Historically, Non-Current Assets has averaged $15.8 million across 5 years, with a median of $14.6 million in 2024.
• Across the five-year window, Non-Current Assets decreased 6.9% in 2022 and jumped 288.41% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $4.3 million in 2022, then surged by 281.81% to $16.4 million in 2023, then climbed by 10.81% to $18.2 million in 2024, then soared by 65.95% to $30.2 million in 2025, then fell by 5.39% to $28.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $28.5 million in Q1 2026, $30.2 million in Q4 2025, and $32.5 million in Q3 2025.